Evercore ISI raised the firm’s price target on AbbVie (ABBV) to $236 from $232 and keeps an Outperform rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- 3 Top Dividend Aristocrat Stocks That Could Hand Investors 20%+ Returns
- AbbVie Stock Forecast: Trending Strong Buy Among Analysts
- AbbVie: Hold Rating Reaffirmed as Skyrizi and Rinvoq Outperformance Potential Drives Price Target Increase to $244 Amid Ongoing Competitive and Pipeline Uncertainties
- Midday Fly By: Alphabet, Meta, Amazon, Microsoft report quarterly beats
- AbbVie price target raised to $278 from $270 at Morgan Stanley